Could a Blood Test Detect Alzheimer’s Changes Before Symptoms Appear?
Could a routine blood draw eventually help identify Alzheimer’s-related changes before noticeable memory problems develop?
Research highlighted in the September 2026 issue of NIH News in Health offers a promising glimpse into that possibility. Scientists found a connection between certain blood markers and declining memory and thinking abilities in middle-aged adults. However, the findings do not establish that every healthy adult should receive an Alzheimer’s blood test.
For patients and families, understanding the difference between early-detection research and testing used to evaluate existing symptoms is essential.
What did the study find?
The study, published in The Lancet on May 30, 2026, analyzed 1,350 participants from the long-running Coronary Artery Risk Development in Young Adults, or CARDIA, study.
Participants ranged from 53 to 69 years old, with an average age of 61. Researchers excluded people with probable dementia and examined blood markers related to amyloid-beta and phosphorylated tau—proteins associated with Alzheimer’s disease.
They compared these markers with cognitive testing, including changes over the preceding five years. Certain abnormal biomarker patterns were associated with poorer processing speed and executive function, which includes skills used to organize and manage tasks. Some markers were also associated with greater odds of accelerated decline in verbal memory or processing speed. The findings were not consistent across every cognitive measure.
This was an observational study. It identified associations; it did not test whether screening people and treating them based on their results prevents dementia.
What can a blood marker tell us?
A biomarker is a measurable biological signal. In this case, researchers examined proteins in blood that may reflect Alzheimer’s-related processes.
These tests do not directly measure someone’s ability to remember appointments, manage finances, or live independently. Cognitive testing and clinical evaluation address those questions.
The NIH summary explains that Alzheimer’s-related changes can begin before obvious symptoms. Studying blood markers in midlife may help researchers understand that earlier period. More research is needed before applying these findings as routine testing for adults without symptoms.
Aren’t Alzheimer’s blood tests already available?
Yes. Blood tests used to help evaluate symptomatic patients are different from general screening of healthy people.
On May 16, 2025, the FDA cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test to help diagnose Alzheimer’s disease in adults age 55 and older who have signs and symptoms.
The test measures a ratio of two proteins associated with amyloid plaques in the brain. It provides a less invasive option than collecting spinal fluid and may reduce reliance on amyloid PET scans.
The FDA specifies that this test is not intended for general screening or use as a stand-alone diagnosis. Results must be interpreted alongside other clinical information, and additional evaluation may be necessary. False-positive, false-negative, and indeterminate results are possible.
The practical distinction is straightforward: helping a specialist investigate existing cognitive symptoms is a different task from predicting future illness in someone who feels well.
Does an abnormal result mean dementia is inevitable?
An abnormal biomarker result should not be treated as a personal timeline for developing dementia.
This study examined relationships across a group of participants. It did not establish when an individual would develop symptoms, whether that person would eventually develop dementia, or whether screening would improve their outcome.
Researchers also found that the proportion classified as biomarker-positive differed depending on which marker they used. That reinforces the importance of understanding the specific test and its intended purpose.
When should memory changes prompt a doctor’s visit?
Occasional forgetfulness can happen in everyday life. Changes that increasingly interfere with normal activities deserve medical attention.
Examples include repeatedly asking the same questions, becoming lost in familiar places, or having new difficulty managing bills, preparing meals, or following directions.
An evaluation can also identify other explanations for thinking or memory problems, including depression, medication effects, or infection. A clinician may review medical history, perform a physical examination, assess thinking and memory, and order appropriate tests.
Rather than beginning with a request for one particular blood test, patients can describe what has changed and how it affects daily life.
Useful questions include:
What could be causing these changes?
Would cognitive testing or a specialist referral help?
Would an Alzheimer’s biomarker test change my care?
What would a positive, negative, or uncertain result mean?
What can readers do now to support brain health?
Research into earlier detection continues, but healthy habits remain relevant today.
NIH describes regular physical activity, a heart-healthy diet, avoiding smoking, and managing cardiovascular risk factors as ways to support a healthier aging brain. Social connection and mentally stimulating activities may also help support brain function. These steps do not guarantee prevention of Alzheimer’s disease.
For families noticing persistent changes, arranging an evaluation is more useful than trying to interpret symptoms through an online checklist or a test result alone.
The new research offers hope for understanding Alzheimer’s earlier. Its immediate value is a clearer picture of how blood markers and cognitive changes may be connected during midlife—and a reminder that testing works best when it answers a specific clinical question.
Sources — full URLs for your website
NIH September 2026 research overview: https://newsinhealth.nih.gov/2026/09/blood-tests-may-flag-early-alzheimer-s
Original study in The Lancet, indexed on PubMed: https://pubmed.ncbi.nlm.nih.gov/42208562/
FDA announcement explaining the cleared test and its limitations: https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease
NIH guidance on recognizing and evaluating cognitive changes: https://newsinhealth.nih.gov/2017/12/dealing-dementia
